Interestingly, consistent with MR Corge estimates, CETP-inhibitors have been a recent focus of drug development yet have not shown effectiveness in reducing cardiovascular disease risks in randomized controlled trials, despite their capacity to significantly elevate serum HDL levels (Nissen et al. 2007, Lincoff et al. 2017). The gene discussed is CETP; the disease is cardiovascular disorder.